Sign up Australia
Proactive Investors - Run By Investors For Investors

Nanobiotix to present at immuno-oncology gathering this month

The company currently has seven clinical trials underway
picture of xray machine
Nanobiotix wants to trial its nano-xray therapy in a combination

Nanobiotix SA (EPN:NANO) has been invited to give two presentations to the Society for Immunotherapy of Cancer (SITC) conference this month for its flagship NBTXR3 treatment.

A pioneering approach to cancer, nanoparticles are injected directly into solid tumours to amplify the effects of shrinking treatment.

It has already demonstrated success tackling soft tissue sarcoma, a cancer that affects muscle, fat and blood vessels.

The company currently has seven clinical trials underway but is also exploring NBTXR3’s potential in immuno-oncology in combination therapies.

An investigational new drug application is being prepared for a combination trial in the US with checkpoint inhibitors, another of promising research in cancer treatment.

In January, meanwhile, first results from a phase I/II trial in liver cancer patients are expected and will be presented to the ASCO GI conference.

View full NANO profile View Profile

Nanobiotix SA Timeline

Related Articles

lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use